Aims: Pleomorphic adenoma gene 1 (PLAG1) gene rearrangement is the most common genetic abnormality in pleomorphic adenoma (PA), resulting in overexpression of PLAG1 protein. PA and carcinoma ex pleomorphic adenoma (CA ex-PA) can mimic various benign and malignant salivary gland tumours. The aims of this study are to evaluate the sensitivity and specificity of PLAG1 immunohistochemistry (IHC) in the differential diagnosis of PA and CA ex-PA and to compare the PLAG1 immunohistochemical results to PLAG1 gene abnormalities as detected by fluorescence in-situ hybridisation (FISH). Methods and results: PLAG1 immunostaining was performed on 83 salivary gland tumours, including 23 PA, 15 CA ex-PA and 45 other salivary gland tumours. In addition, PLAG1 FISH was performed in 44 cases for the presence of gene rearrangements/ amplifications. The results showed high sensitivity of PLAG1 IHC in 96% of PA; however, discordant results between PLAG1 FISH abnormalities and IHC were noted in 15 of 44 cases (34%). Seven PA, four de-novo myoepithelial carcinomas and one basal cell adenocarcinoma had negative FISH results, but were positive for IHC; while three salivary duct carcinomas (SDC) ex-PA were positive for FISH but negative for IHC. PLAG1 IHC can differentiate CA ex-PA from de-novo SDC (P = 0.02), but not from de-novo myoepithelial carcinoma. PLAG1 IHC is a sensitive marker for PA. This could be due to PLAG1 gene abnormalities beyond FISH resolution. Conclusions: A negative PLAG1 IHC might be helpful in excluding a PA diagnosis. Interestingly, in the context of CA ex-PA, FISH is more sensitive than IHC in detecting PLAG1 abnormalities.
Introduction
Pleomorphic adenoma (PA) is the most common salivary gland neoplasm, accounting for approximately 60% of all epithelial salivary gland tumours. 1 Histologically, PA is composed typically of three components of various proportions: epithelial/ductal cells, myoepithelial cells and myxoid/chondroid stroma. 2 However, as PA is known to be associated with marked morphological diversity, distinguishing PA from other salivary gland neoplasms, benign or malignant, may not always be straightforward and may require additional ancillary studies (e.g. immunohistochemistry, cytogenetics and molecular analysis).
Pleomorphic adenoma gene 1 (PLAG1) is a zinc finger transcription factor and a proto-oncogene located on chromosome 8q12. Fusions involving the PLAG1 locus were first discovered in PA in 1997, 3 and have since been reported in 24-88% of PA and carcinoma ex-pleomorphic adenoma (CA ex-PA). 2, [4] [5] [6] [7] PLAG1 fusion appears to be highly specific for PA and CA ex-PA, as it has not been detected in other benign or malignant salivary gland neoplasms. 2, [4] [5] [6] [7] [8] The high prevalence and almost 100% specificity of PLAG1 fusion make it an attractive potential target of ancillary diagnostic tests. As PLAG1 primers for polymerase chain reaction (PCR) and PLAG1 probes for fluorescence in-situ hybridisation (FISH) are not readily available commercially, and as molecular and cytogenetics diagnostic laboratory services are usually provided only in large academic centres, there is a demand to seek for an affordable and feasible alternative testing method for PLAG1 translocation.
Fusions between PLAG1 gene and various partners, including CTNNB1, LIFR, FGFR1 and CHCHD7, leads to overexpression of PLAG1 oncoprotein.
2,4-7 PLAG1 overexpression mediates multiple downstream factors, including the insulin-like growth factor 2 (IGF-2) mitogenic signalling pathway, growth factors and their receptors, tumour suppressors, cell cycle-related proteins and apoptosis-related proteins, which subsequently influence cell proliferation and tumorigenesis. [9] [10] [11] [12] [13] Additionally, PLAG1 alteration has been reported in skin and soft tissue myoepithelioma, 14, 15 lipoblastoma, 16 hepatoblastoma, 17 uterine leiomyoma, 18 uterine endometrial stromal sarcoma 19 and certain types of acute myeloid leukaemia. 10 Several recent studies have shown that PLAG1 overexpression can be detected by immunohistochemistry (IHC), and that PLAG1 IHC is a relatively sensitive marker for PA in surgical and cytological samples. 4, [20] [21] [22] [23] [24] [25] [26] However, most of these studies did not include molecular or cytogenetics assays as the gold standard reference test to confirm the presence of PLAG1 fusion and to evaluate the sensitivity and specificity of PLAG1 IHC in detecting PLAG1 fusion.
In the present study, we aimed to characterise PLAG1 IHC in a large cohort of 83 salivary gland tumours, including PA, CA ex-PA and other types of salivary gland tumours. Moreover, a significant subset of these tumours was examined for PLAG1 fusion in order to determine the sensitivity and specificity of PLAG1 IHC in detecting PLAG1 fusion and in differentiating PA and CA ex-PA from other potential mimics.
Material and methods

C A S E S E L E C T I O N A N D S T U D Y C O H O R T
Eighty-three patients with epithelial salivary gland neoplasms who had surgery at Memorial Sloan Kettering Cancer Center (MSKCC) (New York, NY, USA) between 1995 and 2014, with appropriate material for subsequent IHC and FISH studies, were included. The histological slides were reviewed by a head and neck pathologist (N.K.) to confirm the diagnosis. The study was approved by the MSKCC Institutional Review Board. Informed consent was not required for this retrospective study.
The study cohort was composed of 23 PAs, 15 CAs ex-PA and a control group of 45 other types of salivary gland carcinomas without a PA component (including 10 de-novo myoepithelial carcinomas (MECA), six de-novo salivary duct carcinomas (SDC), four basal cell adenocarcinomas, eight polymorphous adenocarcinoma (PAC), two epithelial-myoepithelial carcinomas (EMC), four mucoepidermoid carcinomas (MEC), five adenoid cystic carcinomas (ACC), five acinic cell carcinomas (AciCC) and one secretory carcinoma (known previously as mammary analogue secretory carcinoma) ( Table 1 ). The histological subtypes of the CAs ex-PA were as follows: SDC (n = 9), MECA (n = 3), carcinoma with squamous and glandular features (n = 1), EMC (n = 1) and one adenocarcinoma not otherwise specified (NOS) (n = 1).
Immunohistochemical stains for PLAG1 were performed using monoclonal antibody clone 3B7 (4 lg/ ml; Novus Biologicals, Littleton, CO, USA). All immunostains were performed on a Leica Bond-3 (Leica, Buffalo Grove, IL, USA) automated stainer platform. Prior to immunohistochemical staining, heat-based antigen retrieval employing a high pH buffer (ER2; Leica) was performed on all slides. As a secondary system, a polymeric detection kit (Refine; Leica) was used. PLAG1 immunopositivity was detected in the nuclei of tumour cells. Both ductal and myoepithelial cells showed positive PLAG1 staining, but the immunopositivity was more prevalent in the myoepithelial cells. A tumour was considered positive for PLAG1 IHC when nuclear immunostain was noted in >5% of tumour cells.
P L A G 1 F L U O R E S C E N C E I N -S I T U H Y B R I D I Z A T I O N ( F I S H )
FISH on interphase nuclei from paraffin-embedded 4-lm sections was performed using custom probes of bacterial artificial chromosomes (BACs) flanking PLAG1 on chromosome 8q12 (Table S1 ) in 44 cases, as described previously. 2 These 44 cases included 15 PA, 12 CAs ex-PA, three de-novo SDCs, six de-novo MECAs, two basal cell adenocarcinoma and six PACs.
Two hundred successive nuclei were examined for the presence of PLAG1 gene rearrangements/amplifications using a Zeiss fluorescence microscope (Zeiss Axioplan, Oberkochen, Germany), controlled by Isis 5 software (Metasystems, Waltham, MA, USA). A positive FISH score was interpreted when at least 20% of the nuclei showed a break-apart signal. Nuclei with an incomplete set of signals were omitted from the score.
S T A T I S T I C A L A N A L Y S I S
All statistical analyses were performed using SPSS software version 22.0 (IBM Corporation, New York, NY, USA). The frequency of tumours with PLAG1 immunopositivity as well as the percentage of positive tumour cells in different tumour types was compared using Fisher's exact test and two-tailed Student's t-test, respectively. P-values less than 0.05 were considered to be statistically significant.
Results
The results of PLAG1 IHC and PLAG1 FISH are shown in Table 2 . PLAG1 IHC was positive in 22 of 23 (96%) PAs ( Figure 1A -C) and nine of 15 (60%) CAs ex-PA (Figure 2A-D) . The sensitivity of PLAG1 immunostaining in predicting PA and CA ex-PA were 96% and 60%, respectively. Five of nine (56%) SDCs ex-PA were positive for PLAG1 IHC, while all six tested de-novo SDCs were negative. PLAG1 IHC could differentiate CA ex-PA from denovo SDC (Fisher's exact test, P = 0.020). Three of three (100%) MECAs ex-PA and seven of 10 (70%) de-novo MECAs were positive for PLAG1 IHC (Figure 2E,F) . PLAG1 was not a useful marker to distinguish CA ex-PA from de-novo MECA (Fisher's exact test, P = 0.601).
Among the tumours in the control group, 11 of 45 tumours demonstrated positive PLAG1 immunostaining, showing a specificity of PLAG1 IHC in predicting the PA component of 74%. The histological types of these 11 tumours were as follows: seven of 10 (70%) de-novo MECAs, two of four (50%) basal cell adenocarcinomas, one of two (50%) EMCs and one of four (25%) MECs. None of the de-novo SDCs (none of six), PACs (none of eight), ACCs (none of five), AciCCs (none of five) or secretory carcinomas (none of one) showed positive staining for PLAG1. The majority of the PAs (15 of 23), CAs ex-PA (eight of 15) and de-novo MECAs (six of 10) exhibited moderate or strong PLAG1 immunolabelling. The percentage of positive tumour cells for PLAG1 IHC expressed as mean AE standard error of mean were 50 AE 4%, 36 AE 7% and 65 AE 10% in PAs, CAs ex-PA and de-novo MECAs, respectively. The percentage of positive staining was significantly lower in CA ex-PA compared to PA (two-tailed Student's t-test, P = 0.008), while there was no significant difference between de-novo MECA and PA (P = 0.90) or between MECA and CA ex-PA (P = 0.07).
The FISH test was performed previously on 44 cases, and the results were reported previously by our group. 2 The correlation between PLAG1 immunoreactivity and PLAG1 fusion status is shown in Table 1 . Overall, PLAG1 IHC had a sensitivity of 80% and specificity of 59% in predicting PLAG1 fusion. Three of 15 tumours with proven PLAG1 fusion on FISH analysis were falsely negative on PLAG1 IHC study. All three cases were CA ex-PA, with the carcinoma component being SDC (n = 2) and carcinoma with squamous and glandular features (or unclassified) (n = 1). Twelve of 30 fusion-negative neoplasms exhibited PLAG1 immunoreactivity, including seven PAs, four de-novo MECAS and one basal cell adenocarcinoma. The specificity of PLAG1 IHC in predicting PLAG1 fusion status was 30% in PA and 100% in CA ex-PA.
Discussion
In 1997, Kas et al. were the first to report PLAG1-CTNNB1 fusion as the key event in the tumorigenesis of pleomorphic adenoma. 3, 27 Since then, multiple groups have confirmed PLAG1 rearrangements as the most prevalent molecular event in pleomorphic adenoma and carcinoma ex-pleomorphic adenoma, affecting 24-88% of the tumours. 2, [4] [5] [6] [7] [8] 27 In these studies, the PLAG1 translocation was detected using techniques that might not be readily available in daily pathology practices, e.g. Northern blot analysis, 5, 6 reverse transcription-PCR (RT-PCR) 4 or FISH. 2, 2, 7, 8 PLAG1 immunohistochemistry might serve as an accessible and feasible alternative. However, the sensitivity and specificity of PLAG1 IHC in detecting PA and PLAG1 fusion has not yet been well established.
Fusion involving PLAG1 locus results in overexpression of PLAG1 oncoprotein, which can be detected by immunohistochemistry. 4, 27 Several recent reports have investigated the utility of PLAG1 IHC as an ancillary tool in diagnosing PA and CA ex-PA in surgical and cytological specimens. The results of these reports are summarised in Table 3 . 4, [20] [21] [22] [23] [24] [25] [26] [27] All but one study have demonstrated that PLAG1 IHC was a highly sensitive marker for PA in surgical specimens, showing positivity in 93-100% of PAs. Only one group has reported a low PLAG1 IHC sensitivity of 62% in 22 lacrimal gland PAs, using the commercially available 3B7 PLAG1 monoclonal antibody (Novus Biologicals, Littleton, CO, USA). 26 However, the same group has previously reported 100% PLAG1 immunopositivity in the same cohort using a customised PLAG1 antibody. 25 In cytological samples, the reported percentage of PLAG1 immunoreactivity in PA was relatively low, at 55-73%, which might be attributed in part to different preparation methods and/or storage media that were utilised in cytology.
Compared to PA, the reported PLAG1 IHC immunopositivity appeared to be more variable in CA ex-PA, ranging from 20% to 100%. 4, 21, 23, [25] [26] [27] In this study, PLAG1 IHC was positive in 60% of the tested CA ex-PA cases. Several mechanisms may explain the wide range of PLAG1 immunopositivity in CA ex-PA. First, many types of salivary gland tumours can show hyalinising stroma mimicking the PA component of CA ex-PA; therefore, some of the reported negative PLAG1 IHC cases of CA ex-PA could have been misclassified. Secondly, PLAG1 oncoprotein overexpression may be lost during the process of tumour progression or malignant transformation, leading to low PLAG1 expression and subsequently negative PLAG1 IHC. Taken together, PLAG1 IHC emerges as a highly sensitive marker for PA but less reliable in detecting CA ex-PA. The reported specificity of PLAG1 IHC as a marker for PA and CA ex-PA seemed to be relatively low. Several previous studies have reported positive PLAG1 IHC in non-PA and non-CA ex-PA tumours (7% and 46%, respectively). 4, 20, 23, 24 In this study, PLAG1 IHC was positive in 29% of other types of tumours. PLAG1-positive staining has been reported in various salivary gland neoplasms, malignant or benign, including myoepithelioma, basal cell adenoma, MECA, ACC, PAC AciCC and poorly differentiated basaloid carcinoma. 4, 20, 23, 24 In the present study, PLAG1 IHC was found positive in a majority (seven of 10; 70%) of de-novo MECA carcinoma, despite none of these tumours showing PLAG1 gene rearrangements by FISH. This result limits the utility of PLAG IHC in distinguishing de-novo MECA from PA, which is not always performed easily by morphology. Additionally, we found PLAG1 to be positive in a proportion of basal cell adenocarcinoma, EMC and mucoepidermoid carcinoma, but not in de-novo SDC, polymorphous adenocarcinoma, ACC, AciCC and secretory carcinoma. In our hands, PLAG1 IHC seems to a helpful immunomarker in distinguishing between de-novo SDC and CA ex-PA, but not between de-novo MECA and CA ex-PA.
Two prior studies have correlated PLAG1 immunoreactivity with PLAG1 fusion status. 4, 27 In one study, using RT-PCR with customised primers for PLAG1 and PLAG1 IHC, Matsuyama et al. have reported that the sensitivity and specificity of PLAG1 IHC in detecting PLAG1 fusion were 100% and 0%, respectively. In the second study, Bahrami et al. 27 reported 67% (12 of 18) of CA ex-PA with PLAG1 fusion and 77% (17 of 22) with positive PLAG1 by IHC. The sensitivity and specificity of PLAG1 IHC in detecting PLAG1 fusion in CA ex-PA were 92% and 17%, respectively. In the present study, the sensitivity and specificity of PLAG1 IHC compared to PLAG1 fusion were 100% and 30% in PA and 70% and 100% in CA ex-PA. Taken together, it appears that PLAG1 IHC is a sensitive but not specific test in predicting PLAG1 fusion. A negative PLAG1 IHC might be helpful in excluding PLAG1 fusion and a PA diagnosis, but a positive PLAG1 IHC may not always predict the existence of PLAG1 fusion. *Data from the present study. †These 76 patients included the 40 patients studied in the above row.
Conclusions
PLAG1 IHC is a sensitive marker and a valuable ancillary test for PA and CA ex-PA, and may point to PLAG1 gene abnormalities that are characteristic in these tumours. Thus, a negative PLAG1 IHC might be more reliable in excluding a PA diagnosis. However, the reverse remains to be determined if PLAG1 IHC expression in the absence of a positive FISH result is non-specific or implies alternative genetic or epigenetic mechanisms beyond the FISH resolution.
